Prima Biomed Ltd engages in the research and commercialization of licensed medical biotechnology products in Australia. The company's primary product CVac, a cancer vaccine that has completed Phase IIB clinical trial, focuses on the development of ex-vivo immunotherapy for ovarian cancer. It also develops a program for the identification and development of monoclonal antibodies to target cripto-1, a protein found on the surface of various cancer cells. The company is collaborated with the University of New South Wales and University of Queensland to create a technology for enabling oral administration of vaccines. Prima Biomed Ltd is based in Sydney, Australia.
